Phaseline

Companies › Portage Biotech

Portage Biotech: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TT-10–Phase 1Renal Cell CancerDec 2028
TT-4–Phase 1Renal Cell CancerDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04969315TT-10Phase 1Renal Cell CancerOncologyDec 2028
NCT04969315TT-4Phase 1Renal Cell CancerOncologyDec 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.